The effect of MAPT H1 and APOE ε4 on transition from mild cognitive impairment to dementia

Area of Science:

• Neuroscience
• Genetics
• Alzheimer's Disease Research

Background:

• Alzheimer's disease (AD) pathogenesis involves microtubule-associated protein tau (MAPT) and apolipoprotein E (APOE).
• Mild cognitive impairment (MCI) is a transitional stage preceding dementia, with varying progression rates.

Purpose of the Study:

• To investigate the impact of MAPT H1/H2 haplotypes and APOE ε4 polymorphisms on the rate of progression from MCI to dementia.
• To determine if these genetic factors independently or additively accelerate cognitive decline in MCI individuals.

Main Methods:

• Prospective longitudinal study of 319 individuals with amnestic MCI across three independent samples.
• Analysis of MAPT H1/H2 haplotypes and APOE ε4 allele status.
• Cox regression models to assess the association between genetic factors and time to progression to dementia.

Main Results:

• APOE ε4 allele carriers showed a 1.47-fold increased rate of progression to dementia, shortening time by 0.87 years.
• MAPT H1/H1 genotype carriers exhibited a 1.45-fold increased rate of progression, shortening time by 1.37 years.
• Combined MAPT H1/H1 and APOE ε4 presence resulted in an additive effect, increasing progression rate 2.24-fold and shortening time by 2.92 years.

Conclusions:

• Both MAPT H1/H1 genotype and APOE ε4 allele are independently associated with accelerated progression from MCI to dementia.
• These genetic factors have an additive effect, significantly increasing the rate and shortening the time to dementia.
• The findings suggest MAPT and APOE genotypes influence AD progression, potentially by affecting amyloid-β and tau deposition.